ALNY

SEC source: 0001735276-24-000104 · edgardoc.xml · nonDerivative · entry 5

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,496

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $251.07 to $252.06. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000104 · edgardoc.xml · nonDerivative · entry 4

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,322

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $250.05 to $251.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000104 · edgardoc.xml · nonDerivative · entry 3

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,640

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $249.00 to $250.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000104 · edgardoc.xml · nonDerivative · entry 2

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,855

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $247.76 to $248.67. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000108 · edgardoc.xml · nonDerivative · entry 1

Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,099

F1 · kind: On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting FDA acceptance of a new drug application submitted for regulatory approval for a therapeutic to treat ATTR amyloidosis with cardiomyopathy after receipt of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 study, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on November 22, 2024.

SEC source: 0001735276-24-000107 · edgardoc.xml · nonDerivative · entry 1

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,139

F1 · kind: On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting FDA acceptance of a new drug application submitted for regulatory approval for a therapeutic to treat ATTR amyloidosis with cardiomyopathy after receipt of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 study, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on November 22, 2024.

SEC source: 0001735276-24-000106 · edgardoc.xml · nonDerivative · entry 1

Poulton Jeffrey V. · CIK 0001782962 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,326

F1 · kind: On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting FDA acceptance of a new drug application submitted for regulatory approval for a therapeutic to treat ATTR amyloidosis with cardiomyopathy after receipt of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 study, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on November 22, 2024.

SEC source: 0001735276-24-000105 · edgardoc.xml · nonDerivative · entry 1

Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,660

F1 · kind: On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting FDA acceptance of a new drug application submitted for regulatory approval for a therapeutic to treat ATTR amyloidosis with cardiomyopathy after receipt of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 study, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on November 22, 2024.

SEC source: 0001735276-24-000104 · edgardoc.xml · nonDerivative · entry 1

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,881

F1 · kind: On February 27, 2023, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting FDA acceptance of a new drug application submitted for regulatory approval for a therapeutic to treat ATTR amyloidosis with cardiomyopathy after receipt of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 study, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on November 22, 2024.

SEC source: 0001735276-25-000062 · edgardoc.xml · nonDerivative · entry 2

Reitan Colleen F · CIK 0001740730 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36

SEC source: 0001735276-24-000098 · edgardoc.xml · nonDerivative · entry 1

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,705

F1 · kind: On February 23, 2016, the People, Culture, and Compensation Committee of the issuer approved the issuance of shares of Company common stock having an aggregate value of USD $50,000 to each employee who completes 10 consecutive years of employment. The shares issued and reported here on Form 4, net of the minimum statutory tax liability, were issued to the reporting person in recognition of 10 years of continuous employment on October 8, 2024.

SEC source: 0001735276-24-000096 · edgardoc.xml · nonDerivative · entry 1

Hesslein Robert W. · CIK 0001585018 · EVP, CLO and Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,245

F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date.

SEC source: 0001735276-25-000062 · edgardoc.xml · nonDerivative · entry 1

Reitan Colleen F · CIK 0001740730 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32

SEC source: 0001735276-24-000085 · edgardoc.xml · derivative · entry 4

Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,352

Underlying: Common Stock · 15,000 shares

Expires 2029-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on March 12, 2024.

F3 · derivative.exercise_date: This stock option was fully vested and exercisable as of February 28, 2023.

SEC source: 0001735276-24-000085 · edgardoc.xml · nonDerivative · entry 2

Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,441

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on March 12, 2024.

SEC source: 0001735276-24-000085 · edgardoc.xml · nonDerivative · entry 1

Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,441

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on March 12, 2024.

SEC source: 0001735276-24-000083 · edgardoc.xml · derivative · entry 11

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,667 shares

Expires 2025-12-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024.

F9 · derivative.exercise_date: This stock option was fully vested and exercisable as of December 7, 2015.

SEC source: 0001735276-24-000083 · edgardoc.xml · derivative · entry 10

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,192

Underlying: Common Stock · 14,058 shares

Expires 2029-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024.

F8 · derivative.exercise_date: This stock option was fully vested and exercisable as of February 28, 2023.

SEC source: 0001735276-24-000083 · edgardoc.xml · nonDerivative · entry 8

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,881

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024.

SEC source: 0001735276-24-000083 · edgardoc.xml · nonDerivative · entry 7

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,016

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $273.32 to $274.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000083 · edgardoc.xml · nonDerivative · entry 6

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,174

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $272.23 to $272.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000083 · edgardoc.xml · nonDerivative · entry 5

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,087

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $271.02 to $271.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000083 · edgardoc.xml · nonDerivative · entry 4

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,823

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $269.90 to $270.87. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000083 · edgardoc.xml · nonDerivative · entry 3

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,485

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024.

F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $268.53 to $269.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000083 · edgardoc.xml · nonDerivative · entry 2

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,906

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024.

SEC source: 0001735276-24-000083 · edgardoc.xml · nonDerivative · entry 1

Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,848

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 10, 2024.

SEC source: 0001735276-24-000080 · edgardoc.xml · derivative · entry 12

Ausiello Dennis A · CIK 0001381994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,250 shares

Expires 2025-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024.

F11 · derivative.exercise_date: This stock option was fully vested and exercisable as of June 1, 2016.

SEC source: 0001735276-24-000080 · edgardoc.xml · derivative · entry 11

Ausiello Dennis A · CIK 0001381994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,000 shares

Expires 2028-06-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024.

F10 · derivative.exercise_date: This stock option was fully vested and exercisable as of June 20, 2019.

SEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 9

Ausiello Dennis A · CIK 0001381994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 136

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024.

F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $266.39 to $266.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 8

Ausiello Dennis A · CIK 0001381994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 398

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024.

F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $264.37 to $265.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 7

Ausiello Dennis A · CIK 0001381994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,030

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $263.29 to $264.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 6

Ausiello Dennis A · CIK 0001381994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,438

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $262.26 to $263.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 5

Ausiello Dennis A · CIK 0001381994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,805

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $261.21 to $262.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 4

Ausiello Dennis A · CIK 0001381994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,017

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $259.87 to $260.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 3

Ausiello Dennis A · CIK 0001381994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,759

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024.

F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $258.85 to $259.85. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 2

Ausiello Dennis A · CIK 0001381994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,386

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024.

SEC source: 0001735276-24-000080 · edgardoc.xml · nonDerivative · entry 1

Ausiello Dennis A · CIK 0001381994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,386

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: All transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on May 3, 2024.

SEC source: 0001735276-24-000077 · edgardoc.xml · derivative · entry 4

Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,352

Underlying: Common Stock · 15,148 shares

Expires 2029-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on March 12, 2024.

F3 · derivative.exercise_date: The stock option was fully vested as of 02/28/2023.

SEC source: 0001735276-24-000077 · edgardoc.xml · nonDerivative · entry 2

Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,441

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on March 12, 2024.

SEC source: 0001735276-24-000077 · edgardoc.xml · nonDerivative · entry 1

Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,589

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on March 12, 2024.

SEC source: 0001735276-24-000075 · edgardoc.xml · nonDerivative · entry 1

Greenstreet Yvonne · CIK 0001446125 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,441

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on March 12, 2024.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 13

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,609

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $235.10 to $235.73. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 12

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,828

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $234.06 to $235.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 11

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,070

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $233.00 to $234.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 10

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,221

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $231.97 to $232.97. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 9

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,504

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $230.92 to $231.78. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 8

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,633

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $229.76 to $230.70. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 7

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,031

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $228.75 to $229.72. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 6

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,379

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $227.72 to $228.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

SEC source: 0001735276-24-000069 · edgardoc.xml · nonDerivative · entry 5

Garg Pushkal · CIK 0001829252 · CMO & EVP Dev & Med Affairs

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,548

F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form.

F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $226.45 to $227.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.